Antidepressant-like effects of δ opioid receptor agonists in animal models

Current Neuropharmacology

Volumn 10, Issue 3, 2012, Pages 231-238

  Saitoh, Akiyoshi ^a   Yamada, Mitsuhiko ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

Author keywords

Anxiety; Depression; KNT 127; Naltrindole; SNC80; TAN 67

Indexed keywords

1,2,3,4,4A,5,12,12AALPHA OCTAHYDRO 4AALPHA (3 HYDROXYPHENYL) 2 METHYLQUINOLINO[2,3 G]ISOQUINOLINE; 4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 HYDROXYBENZYL] N,N DIETHYLBENZAMIDE; 4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; ADL 5859; ANTIDEPRESSANT AGENT; AZD 2327; BETA ENDORPHIN; BRAIN DERIVED NEUROTROPHIC FACTOR; BUPRENORPHINE; DELTA OPIATE RECEPTOR AGONIST; ENADOLINE; FLUVOXAMINE; IMIPRAMINE; KNT 127; MILNACIPRAN; MORPHINE; NIH 11082; OXYCODONE; OXYMORPHONE; UFP 512; UNCLASSIFIED DRUG;

ANTIDEPRESSANT ACTIVITY; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; ELECTROCONVULSIVE THERAPY; FORCED SWIMMING TEST; HUMAN; MAJOR DEPRESSION; NONHUMAN; OLFACTORY BULBECTOMY; REVIEW;

EID: 84867511725     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/157015912803217314     Document Type: Review

References (71)

1. Wittchen, H.U.; Knäuper, B.; Kessler, R.C. Lifetime risk of depression. Br. J. Psychiatry, 1994, 26, Suppl, 16-22.
2. Kessler, R.C.; Berglund, P.; Demler, O.; Jin, R.; Merikangas, K.R. Walters, E.E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry, 2005, 62, 593-602.
3. Rush, A.J.; Trivedi, M.H.; Wisniewski, S.R.; Nierenberg, A.A. Stewart, J.W.; Warden, D.; Niederehe, G.; Thase, M.E.; Lavori, P.W.; Lebowitz, B.D.; McGrath, P.J.; Rosenbaum, J.F.; Sackeim, H.A.; Kupfer, D.J.; Luther, J.; Fava, M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry, 2006, 163(11), 1905-1917.
4. Broom, D.C.; Jutkiewicz, E.M.; Rice, K.C.; Traynor, J.R.; Woods, J.H. Behavioral effects of delta-opioid receptor agonists: potential antidepressants? Jpn. J. Pharmacol., 2002, 90, 1-6.
5. Jutkiewicz, E.M. The antidepressant-like effects of delta-opioid receptor agonists. Mol. Interv., 2006, 6(3), 162-169.
6. Berrocoso, E.; Sánchez-Blázquez, P.; Garzón, J.; Mico, J.A. Opiates as antidepressants. Curr. Pharm. Des., 2009, 15(14), 1612-1622.
7. Pradhan, A.A.; Befort, K.; Nozaki, C.; Gavériaux-Ruff, C. Kieffer, B.L. The delta opioid receptor: an evolving target for the treatment of brain disorders. Trends. Pharmacol. Sci., 2011, 32(10), 581-590.
8. Darko, D.F.; Risch, S.C.; Gillin, J.C.; Golshan, S. Association of beta-endorphin with specific clinical symptoms of depression. Am. J. Psychiatry, 1992, 149(9), 1162-1167.
9. Djurović, D.; Milić-Askrabić, J.; Majkić-Singh, N. Serum beta-endorphin level in patients with depression on fluvoxamine, FARMACO, 1999, 54(3),130-133.
10. Emrich, H.M.; Hollt, V.; Kissling, W.; Fischler, M.; Laspe, H. Heinemann, H.; von Zerssen, D.; Herz, A. b-Endorphin-like immunoreactivity in cerebrospinal fluid and plasma of patients with schizophrenia and other neuropsychiatric disorders. Pharmacopsychiatry, 1979, 12, 269-276.
11. Inturrisi, C.E.; Alexopoulos, G.; Lipman, R.; Foley, K.; Rossier, J. β-Endorphin immunoreactivity in the plasma of psychiatric patients receiving electroconvulsive treatment. Ann. N.Y. Acad. Sci., 1982, 398, 413-423.
12. Kline, N.S.; Li, C.H.; Lehmann, H.E.; Lajtha, A.; Laski, E.; Cooper, T. β-Endorphin-induced changes in schizophrenic and depressed patients. Arch. Gen. Psychiatry, 1977, 34, 1111-1113.
13. Bodkin, J.A.; Zornberg, G.L.; Lukas, S.E.; Cole, J.O. Buprenorphine treatment of refractory depression. J. Clin. Psychopharmacol., 1995, 15(1), 49-57.
14. Stoll, A.L.; Rueter, S. Treatment augmentation with opiates in severe and refractory major depression. Am. J. Psychiatry, 1999, 156(12), 2017.
15. Hollister, L.E.; Johnson, K.; Boukhabza, D.; Gillespie, H.K. Aversive effects of naltrexone in subjects not dependent on opiates. Drug ALC. Depend., 1981, 8, 37-41.
16. Evans, C.J.; Keith Jr, D.E.; Morrison, H.; Magendzo, K.; Edwards, R.H. Cloning of a delta opioid receptor by functional expression. Science, 1992, 258, 1952-1955.
17. Kieffer, B.L.; Befort, K.; Gaveriaux-Ruff, C.; Hirth, C.G. The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proc. Natl. Acad. Sci. U.S.A., 1992, 89, 12048-12052.
18. Le Merrer, J.; Becker, J.A.; Befort, K.; Kieffer, B.L. Reward processing by the opioid system in the brain. Physiol. Rev., 2009, 89, 1379-1412.
19. Madar, I.; Lever, J.R.; Kinter, C.M.; Scheffel, U.; Ravert, H.T. Musachio, J.L.; Mathews, W.B.; Dannals, R.F.; Frost, J.J. Imaging of delta opioid receptors in human brain by N1-([11C]methyl) naltrindole and PET. Synapse, 1996, 24, 19-28.
20. Porsolt, R.D.; Le Pichon, M.; Jalfre, M. Depression: a new animal model sensitive to antidepressant treatments. Nature, 1977, 266, 730-732.
21. Cryan, J.F.; Markou, A.; Lucki, I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol. Sci., 2002, 23(5), 238-245.
22. Cryan, J.F.; Valentino, R.J.; Lucki, I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci. Biobehav. Rev., 2005, 29(4-5), 547-569.
23. Broom, D.C.; Jutkiewicz, E.M.; Folk, J.E.; Traynor, J.R. Rice, K.C.; Woods, J.H. Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats. Neuropsychopharmacology, 2002d, 26, 744-755.
24. Jutkiewicz, E.M.; Rice, K.C.; Woods, J.H.; Winsauer, P.J. Effects of the delta-opioid receptor agonist SNC80 on learning relative to its antidepressant-like effects in rats. Behav. Pharmacol., 2003, 14, 509-516.
25. Detke, M.J.; Rickels, M.; Lucki, I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl.), 1995, 121, 66-72.
26. Rénéric, J.P.; Lucki, I. Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test. Psychopharmacology (Berl.), 1998, 136, 190-197.
27. Barros, H.M. T.; Ferigolo, M. Ethopharmacology of imipramine in the forced-swimming test: gender differences. Neurosci. Biobehav. Rev., 1998, 23, 279-286.
28. Rénéric, J.P.; Bouvard, M.; Stinus, L. In the rat forced swimming test, chronic but not subacute administration of dual 5-HT/NA antidepressant treatments may produce greater effects than selective drugs. Behav. Brain Res., 2002, 136, 521-532.
29. Nagase, H.; Tanaka, T.; Saitoh, A. Therapeutics of preventive medicines for mood disorders or anxiety disorders. U.S. Patent WO/2002/002117, October 1, 2002.
30. Saitoh, A.; Kimura, Y.; Suzuki, T.; Kawai, K.; Nagase, H.; Kamei, J. Potential anxiolytic and antidepressant-like activities of SNC80, a selective delta-opioid agonist, in behavioral models in rodents. J. Pharmacol. Sci., 2004, 95, 374-380.
31. Nagase, H.; Nemoto, T.; Matsubara, A.; Saito, M.; Yamamoto, N. Osa, Y.; Hirayama, S.; Nakajima, M.; Nakao, K.; Mochizuki, H.; Fujii, H. Design and synthesis of KNT-127, a delta-opioid receptor agonist effective by systemic administration. Bioorg. Med. Chem. Lett., 2010, 20, 6302-6205.
32. Nagase, H.; Osa, Y.; Nemoto, T.; Fujii, H.; Imai, M.; Nakamura, T.; Kanemasa, T.; Kato, A.; Gouda, H.; Hirono, S. Design and synthesis of novel delta opioid receptor agonists and their pharmacologies. Bioorg. Med. Chem. Lett., 2009, 19, 2792-2795.
33. Kameyama, T.; Nagasaka, M.; Yamada, K. Effects of antidepressant drugs on a quickly-learned conditioned-suppression response in mice. Neuropharmacology, 1985, 24(4), 285-290.
34. Inoue, T.; Tsuchiya, K.; Koyama, T. Serotonergic activation reduces defensive freezing in the conditioned fear paradigm. Pharmacol. Biochem. Behav., 1996, 53(4), 825-831.
35. Miyamoto, J.; Tsuji, M.; Takeda, H.; Nawa, H.; Matsumiya, T. Pretreatment with diazepam suppresses the reduction in defensive freezing behavior induced by fluvoxamine in the conditioned fear stress paradigm in mice. Eur. J. Pharmacol., 2000, 409(1), 81-84.
36. Kameyama, T.; Nagasaka, M. Effects of apomorphine and diazepam on a quickly learned conditioned suppression in rats. Pharmacol. Biochem. Behav., 1982, 17(1), 59-63.
37. Fanselow, M.S.; Helmstetter, F.J. Conditional analgesia, defensive freezing, and benzodiazepines. Behav. Neurosci., 1988, 102(2), 233-243.
38. Naidu, P.S.; Lichtman, A.H.; Archer, C.C.; May, E.L.; Harris, L.S.; Aceto, M.D. NIH 11082 produces anti-depressant-like activity in the mouse tail-suspension test through a delta-opioid receptor mechanism of action. Eur. J. Pharmacol., 2007, 566(1-3), 132-136.
39. Vergura, R.; Balboni, G.; Spagnolo, B.; Gavioli, E.; Lambert, D.G. McDonald, J.; Trapella, C.; Lazarus, L.H.; Regoli, D.; Guerrini, R.; Salvadori, S.; Caló, G. Anxiolytic-and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist. Peptides, 2008, 29(1), 93-103.
40. Le Bourdonnec, B.; Windh, R.T.; Ajello, C.W.; Leister, L.K.; Gu, M.; Chu, G.H.; Tuthill, P.A.; Barker, W.M.; Koblish, M.; Wiant, D.D.; Graczyk, T.M.; Belanger, S.; Cassel, J.A.; Feschenko, M.S.; Brogdon, B.L.; Smith, S.A.; Christ, D.D.; Derelanko, M.J.; Kutz, S.; Little, P.J.; DeHaven, R.N.; DeHaven-Hudkins, D.L.; Dolle, R.E. Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro [chromene-2,4-piperidine]-4-yl)benzamide (ADL5859). J. Med. Chem., 2008, 51, 5893-5896.
41. Hudzik, T.J.; Maciag, C.; Smith, M.A.; Caccese, R.; Pietras, M.R. Bui, K.H.; Coupal, M.; Adam, L.; Payza, K.; Griffin, A.; Smagin, G.; Song, D.; Swedberg, M.D.; Brown, W. Preclinical pharmacology of AZD2327-a highly selective agonist of the d opioid receptor. J. Pharmacol. Exp. Ther., 2011, 338(1), 195-204.
42. Kelly, J.P.; Wrynn, A.S.; Leonard, B.E. The olfactory bulbectomized rat as a model of depression: an update. Pharmacol. Ther., 1997, 74, 299-316.
43. Song, C.; Leonard, B.E. The olfactory bulbectomised rat as a model of depression. Neurosci. Biobehav. Rev., 2005, 29, 627-647.
44. Okuyama, S.; Chaki, S.; Kawashima, N.; Suzuki, Y.; Ogawa, S. Nakazato, A.; Kumagai, T.; Okubo, T.; Tomisawa, K. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001. J. Pharmacol. Exp. Ther., 1999, 289, 926-935.
45. Redmond, A.M.; Kelly, J.P.; Leonard, B.E. Behavioural and neurochemical effects of dizocilpine in the olfactory bulbectomized rat model of depression. Pharmacol. Biochem. Behav., 1997, 58, 355-359.
46. Jaako-Movits, K.; Zharkovsky, T.; Pedersen, M.; Zharkovsky, A. Decreased hippocampal neurogenesis following olfactory bulbectomy is reversed by repeated citalopram administration. Cell Mol. Neurobiol., 2006, 26(7-8), 1559-1570.
47. Keilhoff, G.; Becker, A.; Grecksch, G.; Bernstein, H.G.; Wolf, G. Cell proliferation is influenced by bulbectomy and normalized by imipramine treatment in a region-specific manner. Neuropsychopharmacology, 2006, 31(6), 1165-1176.
48. Cryan, J.F.; McGrath, C.; Leonard, B.E.; Norman, T.R. Onset of the effects of the 5-HT1A antagonist, WAY-100635, alone, and in combination with paroxetine, on olfactory bulbectomy and 8-OH-DPAT-induced changes in the rat. Pharmacol. Biochem. Behav., 1999, 63, 333-338.
49. Pandey, D.K.; Mahesh, R.; Kumar, A.A; Rao, V.S.; Arjun, M. Rajkumar, R. A novel 5-HT(2A) receptor antagonist exhibits antidepressant-like effects in a battery of rodent behavioural assays: approaching early-onset antidepressants. Pharmacol. Biochem. Behav., 2010, 94, 363-373.
50. Takahashi, K.; Murasawa, H.; Yamaguchi, K.; Yamada, M. Nakatani, A.; Yoshida, M.; Iwai, T.; Inagaki, M.; Yamada, M.; Saitoh, A. Riluzole rapidly attenuates hyperemotional responses in olfactory bulbectomized rats, an animal model of depression. Behav. Brain Res., 2011, 216(1), 46-52.
51. Saitoh, A; Yamaguchi, K; Tatsumi, Y; Murasawa, H; Nakatani, A Hirose, N; Yamada, M; Yamada, M; Kamei J. Effects of milnacipran and fluvoxamine on hyperemotional behaviors and the loss of tryptophan hydroxylase-positive cells in olfactory bulbectomized rats. Psychopharmacology (Berl.), 2007, 191(4), 857-865.
52. Saitoh, A.; Yamada, M.; Takahashi, K.; Yamaguchi, K.; Murasawa, H.; Nakatani, A.; Tatsumi, Y.; Hirose, N.; Kamei, J. Antidepressant-like effects of the delta-opioid receptor agonist SNC80 ([(+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide) in an olfactory bulbectomized rat model. Brain Res., 2008, 1208, 160-169.
53. Takahashi, K.; Saitoh, A.; Yamada, M.; Maruyama, Y.; Hirose, N. Kamei, J.; Yamada, M. Gene expression profiling reveals complex changes in the olfactory bulbectomy model of depression after chronic treatment with antidepressants. J. Pharmacol. Sci., 2008, 108, 320-34.
54. Torregrossa, M.M.; Folk, J.E., Rice, K.C., Watson, S.J., Woods, J.H. Chronic administration of the delta opioid receptor agonist (+)BW373U86 and antidepressants on behavior in the forced swim test and BDNF mRNA expression in rats. Psychopharmacology, 2005, 183, 31-40.
55. Watanabe, A.; Tohyama, Y.; Nguyen, K.Q.; Hasegawa, S. Debonnel, G.; Diksic, M. Regional brain serotonin synthesis is increased in the olfactory bulbectomy rat model of depression: an autoradiographic study. J. Neurochem., 2003, 85(2), 469-475.
56. Hasegawa, S.; Watanabe, A.; Nguyen, K.Q.; Debonnel, G.; Diksic, M. Chronic administration of citalopram in olfactory bulbectomy rats restores brain 5-HT synthesis rates: an autoradiographic study. Psychopharmacology (Berl.), 2005, 179(4), 781-790.
57. Jenny, M.; Winkler, C.; Spetea, M.; Schennach, H.; Schmidhammer, H.; Fuchs, D. Non-peptidic delta-opioid receptor antagonists suppress mitogen-induced tryptophan degradation in peripheral blood mononuclear cells in vitro. Immunol. Lett., 2008, 118(1), 82-87.
58. Torregrossa, M.M.; Isgor, C.; Folk, J.E.; Rice, K.C.; Watson, S.J. Woods, J.H. The delta-opioid receptor agonist (+) BW373U86 regulates BDNF mRNA expression in rats. Neuropsychopharmacology, 2004, 29, 649-659.
59. Torregrossa, M.M.; Jutkiewicz, E.M.; Mosberg, H.I.; Balboni, G. Watson, S.J.; Woods, J.H. Peptidic delta opioid receptor agonists produce antidepressant-like effects in the forced swim test and regulate BDNF mRNA expression in rats. Brain Res., 2006, 1069, 172-181.
60. Siuciak, J.A.; Clark, M.S.; Rind, H.B.; Whittemore, S.R.; Russo, A.F. BDNF induction of tryptophan hydroxylase mRNA levels in the rat brain. J Neurosci Res. 1998, 52, 149-158.
61. Narita, M.; Kuzumaki, N.; Miyatake, M.; Sato, F.; Wachi, H. Seyama, Y.; Suzuki, T. Role of delta-opioid receptor function in neurogenesis and neuroprotection. J. Neurochem., 2006, 97(5),1494-1505.
62. Saitoh, A.; Sugiyama, A.; Nemoto, T.; Fujii, H.; Wada, K.; Oka, J. Nagase, H.; Yamada, M. The novel δ opioid receptor agonist KNT-127 produces antidepressant-like and antinociceptive effects in mice without producing convulsions. Behav. Brain Res., 2011, 223(2), 271-279.
63. Tortella, F.C.; Echevarria, E.; Robles, L.; Mosberg, H.I.; Holaday, J.W. Anticonvulsant effects of mu (DAGO) and delta (DPDPE) enkephalins in rats. Peptides, 1988, 9(5), 1177-81.
64. Comer, SD.; Hoenicke, E.M.; Sable, A.I.; McNutt, R.W.; Chang, K.-J.; De Costa, B.R.; Mosberg, H.I.; Woods, J.H: Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice. J. Pharmacol. Exp. Ther., 1993, 267, 888-895.
65. Broom, D.C.; Jutkiewicz, E.M.; Folk, J.E.; Traynor, J.R.; Rice, K.C.; Woods, J.H. Convulsant activity of a non-peptidic delta-opioid receptor agonist is not required for its antidepressant-like effects in Sprague-Dawley rats. Psychopharmacology (Berl.), 2002, 164, 42-48.
66. Aceto, MD.; May, E.L.; Harris, L.S.; Bowman, E.R.; Cook, C.D. Pharmacological studies with a nonpeptidic, delta-opioid (-)-(1R,5R,9R)-5,9-dimethyl-2'-hydroxy-2-(6-hydroxyhexyl)-6,7-benzomorphanhydrochloride ((-)-NIH 11082). Eur. J. Pharmacol., 2007, 566(1-3),88-93.
67. Petrillo, P.; Angelici, O.; Bingham, S.; Ficalora, G.; Garnier, M. Zaratin, P.F.; Petrone, G.; Pozzi, O.; Sbacchi, M.; Stean, T.O.; Upton, N; Dondio, G.M.; Scheideler, M.A. Evidence for a selective role of the delta-opioid agonist [8R-(4bS*,8aalpha,8abeta,12bbeta)] 7,10-Dimethyl-1-methoxy-11-(2-methylpropyl)oxycarbonyl5,6,7,8, 12,12b-hexahydro-(9H)-4,8-methanobenzofuro[3,2-e]pyrrolo[2,3-g]isoquinoline hydrochloride (SB-235863) in blocking hyperalgesia associated with inflammatory and neuropathic pain responses. J. Pharmacol. Exp. Ther., 2003, 307(3), 1079-89.
68. Codd, E.E.; Carson, J.R.; Colburn, R.W.; Stone, D.J.; Van Besien, C.R.; Zhang, S.P.; Wade, P.R.; Gallantine, E.L.; Meert, T.F.; Molino, L.; Pullan, S.; Razler, C.M.; Dax, S.L.; Flores, C.M. JNJ-20788560 [9-(8-azabicyclo[3.2.1]oct-3-ylidene)-9H-xanthene-3-carboxylic acid diethylamide], a selective delta opioid receptor agonist, is a potent and efficacious antihyperalgesic agent that does not produce respiratory depression, pharmacologic tolerance, or physical dependence. J. Pharmacol. Exp. Ther., 2009, 329, 241-251.
69. Le Bourdonnec, B.; Windh, R.T.; Leister, L.K.; Zhou, Q.J.; Ajello, C.W.; Gu, M.; Chu, G.H.; Tuthill, P.A.; Barker, W.M.; Koblish, M.; Wiant, D.D.; Graczyk, T.M.; Belanger, S.; Cassel, J.A.; Feschenko, M.S.; Brogdon, B.L.; Smith, S.A.; Derelanko, M.J.; Kutz, S.; Little, P.J.; DeHaven, R.N.; DeHaven-Hudkins, D.L.; Dolle, R.E. Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4-piperidine]-4-yl) benzamide (ADL5747). J. Med. Chem., 2009, 52, 5685-5702.
70. Portoghese, P.S. Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists. Trends Pharmacol. Sci., 1989, 10, 230-235.
71. Pradhan, A.A.; Becker, J.A.; Scherrer, G.; Tryoen-Toth, P.; Filliol, D.; Matifas, A.; Massotte, D.; Gavériaux-Ruff, C.; Kieffer, B.L. In vivo delta opioid receptor internalization controls behavioral effects of agonists. PLoS One, 2009, 4(5), e5425.